Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
The estimates varied substantially by Sociodemographic Index quintile, highlighting global inequities in cancer burden
Findings from a multi-basket MyPathway study
It also approved gallium Ga 68 gozetotide, a radioactive diagnostic agent for PET of PSMA-positive lesions
New indication concerns the treatment of adult patients with previously untreated diffuse large B-cell lymphoma
Efficacy was evaluated using real-world data from the EPIK-P1 study
Findings from the NCI-COG Pediatric MATCH screening Protocol
Evidence for efficacy is based on results from the RELATIVITY-047 study
Subgroup analysis by PD-L1 combined positive score in KEYNOTE-048 study
Findings from the single-arm phase II study
New indications concern the treatment of patients with MSI-H or dMMR advanced colorectal, endometrial, gastric, small intestine, or biliary cancers, and PD-L1-positive metastatic cervical cancer
Long-term outcomes and exploratory analyses from the BILCAP study
It also approved the VENTANA MMR RxDx Panel as a companion diagnostic device to select patients with dMMR in solid tumours
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
